<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Incidence of Primary Endpoint Events</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<thead>
<tr>
<td valign="top"> </td>
<td align="center" colspan="2" valign="top"> Incidence</td>
<td align="center" valign="top"> Risk Reduction</td>
<td align="center" valign="top"> 95% C.I.</td>
<td align="center" valign="top"> p-Value</td>
</tr>
<tr>
<td valign="top"> </td>
<td align="center" valign="top"> Losartan</td>
<td align="center" valign="top"> Placebo</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top"> <br/>Primary Composite Endpoint</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>43.5%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>47.1%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>16.1%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>2.3% to 27.9%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>0.022</td>
</tr>
<tr>
<td colspan="6" rowspan="1" valign="top">  <br/> Doubling of Serum Creatinine, ESRD and Death Occurring as a First Event</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">       Doubling of Serum Creatinine</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 21.6%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 26.0%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">       ESRD</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 8.5%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 8.5%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">       Death</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 13.4%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 12.6%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
<td align="center" colspan="1" rowspan="1" valign="top"> <br/>
</td>
</tr>
<tr>
<td colspan="6" rowspan="1" valign="top"> <br/>Overall Incidence of Doubling of Serum Creatinine, ESRD and Death</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">      Doubling of Serum Creatinine</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 21.6%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 26.0%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 25.3%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 7.8% to 39.4%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 0.006</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">      ESRD</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 19.6%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 25.5%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 28.6%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 11.5% to 42.4%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 0.002</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">      Death</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 21.0%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 20.3%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> -1.7%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> -26.9% to 18.6%</td>
<td align="center" colspan="1" rowspan="1" valign="top"> 0.884</td>
</tr>
</tbody>
</table>